Table 3 Association between groups for the 17 polymorphisms investigated
GENE | PATIENTS n (%) | CONTROLS n (%) | p c | OR (95% CI) d |
|---|---|---|---|---|
IL1A (rs3783553) | ||||
Ins / Ins | 64 (23.2%) | 30 (20.7%) | ||
Ins / Del | 128 (46.4%) | 70 (48.3%) | 0.844 | 0.934 (0.472–1.847) |
Del / Del | 84 (30.4%) | 45 (31.0%) | ||
Ins | 0.46 | 0.45 | ||
Del | 0.54 | 0.55 | ||
TYMS (rs151264360) | ||||
Ins / Ins | 53 (19.2%) | 14 (09.7%) | ||
Ins / Del | 120 (43.5%) | 66 (45.5%) | 0.202 | 1.719 (0.78–3.950) |
Del / Del | 103 (37.3%) | 65 (44.8%) | ||
Ins | 0.41 | 0.32 | ||
Del | 0.59 | 0.68 | ||
UGT1A1 (rs8175347) | ||||
Ins / Ins | 116 (42.6%) | 65 (46.1%) | ||
Ins / Del | 115 (42.3%) | 55 (39.0%) | 0,132 | 0.978 (0.950–1.007) |
Del / Del | 41 (15.1%) | 21 (14.9%) | ||
Ins | 0.64 | 0.66 | ||
Del | 0.36 | 0.34 | ||
CYP2A1 (rs17880560) | ||||
Ins / Ins | 241 (86.3%) | 120 (82.8%) | ||
Ins / Del | 37 (13.3%) | 25 (17.2%) | 0.101 | 1.842 (0.887–3.825) |
Del / Del | 1 (0.40%) | 0 (0%) | ||
Ins | 0.93 | 0.91 | ||
Del | 0.07 | 0.09 | ||
SGSM03 (rs56228771) | ||||
Ins / Ins | 108 (39.1%) | 74 (51.0%) | ||
Ins / Del | 122 (44.2%) | 57 (39.3%) | 0.326 | 0.752 (0.427–1.327) |
Del / Del | 46 (16.7%) | 14 (9.7%) | ||
Ins | 0.61 | 0.71 | ||
Del | 0.39 | 0.29 | ||
IL4 (rs79071878) | ||||
Ins / Ins | 43 (15.6%) | 21 (14.5%) | ||
Ins / Del | 133 (48.2%) | 68 (46.9%) | 0.631 | 0.829 (0.384–1.786) |
Del / Del | 100 (36.2%) | 56 (38.6%) | ||
Ins | 0.4 | 0.38 | ||
Del | 0.6 | 0.62 | ||
MDM2 (rs3730485) | ||||
Ins / Ins | 18 (6.5%) | 11 (7.6%) | ||
Ins / Del | 122 (44.2%) | 58 (40.0%) | 0,174 | 0.457 (0.148–1.412) |
Del / Del | 136 (49.3%) | 76 (52.4%) | ||
Ins | 0.29 | 0.23 | ||
Del | 0.71 | 0.72 | ||
ACE (rs4646994) | ||||
Ins / Ins | 17 (6.0%) | 11 (7.6%) | ||
Ins / Del | 120 (42.4%) | 49 (33.8%) | 0.005 | 0.465 (0.272–0.794) |
Del / Del | 146 (51.6%) | 85 (58.6%) | ||
Ins | 0.27 | 0.25 | ||
Del | 0.73 | 0.75 | ||
CCR5 (rs333) | ||||
Ins / Ins | 1 (0.4%) | 0 (0.0%) | ||
Ins / Del | 18 (6.5%) | 15 (10.3%) | 0.413 | 0.680 (0.270–1.712) |
Del / Del | 257 (93.1%) | 130 (89.7%) | ||
Ins | 0.03 | 0.05 | ||
Del | 0.97 | 0.95 | ||
UCP2 (no rs) | ||||
Ins / Ins | 131 (47.5%) | 74 (51.0%) | ||
Ins / Del | 113 (40.9%) | 57 (39.3%) | 0.361 | 0.774 (0.447–1.340) |
Del / Del | 32 (11.6%) | 14 (9.7%) | ||
Ins | 0.68 | 0.71 | ||
Del | 0.32 | 0.29 | ||
HLA-G (rs371194629) | ||||
Ins / Ins | 77 (26.0%) | 49 (33.8%) | ||
Ins / Del | 144 (48.6%) | 72 (49.6%) | 0,635 | 0.866 (0.478–1.568) |
Del / Del | 75 (25.3%) | 24 (16.6%) | ||
Ins | 0.44 | 0.58 | ||
Del | 0.56 | 0.41 | ||
XRCC1 (rs3213239) | ||||
Ins / Ins | 13 (7.4%) | 10 (6.9%) | ||
Ins / Del | 88 (50.0%) | 56 (38.6%) | 0.109 | 0.390 (0.123–1.234) |
Del / Del | 175 (42.6%) | 79 (54.5%) | ||
Ins | 0.21 | 0.26 | ||
Del | 0.79 | 0.74 | ||
TP53 (rs17880560) | ||||
Ins / Ins | 196 (71.0%) | 101 (69.7%) | ||
Ins / Del | 74 (26.8%) | 42 (29.0%) | 0.610 | 1.64 (0.649–2.087) |
Del / Del | 6 (2.2%) | 2 (1.4%) | ||
Ins | 0.84 | 0.84 | ||
Del | 0.16 | 0.16 | ||
miR-146A (rs2910164) | ||||
CC | 128 (46.6%) | 67 (47.9%) | ||
GC | 123 (44.7%) | 57 (40.7%) | 0.256 | 1.753 (0.666–4.617) |
GG | 24 (8.7%) | 16 (11.4%) | ||
C | 0.69 | 0.68 | ||
G | 0.31 | 0.32 | ||
miR-192A (rs11614913) | ||||
TT | 23 (8.4%) | 9 (6.7%) | ||
CT | 119 (43.4%) | 55 (40.7%) | 0.113 | 1.578 (0.888–2.773) |
CC | 132 (48.2%) | 71 (52.6%) | ||
T | 0.3 | 0.27 | ||
C | 0.7 | 0.73 | ||
miR-499 (rs3746444) | ||||
GG | 21 (7.4%) | 10 (6.9%) | ||
GA | 111 (39.2%) | 55 (37.9%) | 0.166 | 0.717 (0.447–1.149) |
AA | 151 (53.4%) | 80 (55.2%) | ||
G | 0.27 | 0.26 | ||
A | 0.73 | 0.74 | ||
miR-149 (rs2292832) | ||||
CC | 36 (13.2%) | 19 (13.2%) | ||
TC | 115 (42.3%) | 66 (45.8%) | 0.206 | 0.639 (0.320–1.279) |
TT | 121 (44.5%) | 59 (41.0%) | ||
C | 0.34 | 0.36 | ||
T | 0.65 | 0.63 | ||